Lymphoma-Associated Ascites and Pleural Effusion

Epidemiology and Frequency

Pleural effusions occur in approximately 10% of all malignant pleural effusions and develop in 20-30% of patients with lymphoma, with the incidence varying by study, ranging from 5-33% in Hodgkin's disease and similar rates in non-Hodgkin's lymphoma, according to the American Thoracic Society 1
Ascites is much less common than pleural effusion in lymphoma, with peritoneal cavity involvement being uncommon compared to pleural involvement, and when present, ascites represents an indication for treatment initiation in follicular lymphoma, as recommended by the European Society for Medical Oncology 2, 3

In Hodgkin's disease, effusions primarily result from obstruction of lymphatic drainage by enlarged mediastinal lymph nodes, as reported by the American College of Chest Physicians 1
In non-Hodgkin's lymphoma, effusions occur predominantly through direct tumor infiltration of the parietal or visceral pleura, according to the American Thoracic Society 1

Pleural effusions may be unilateral or bilateral, with bilateral presentations occurring in a minority of cases, and dyspnea is the chief symptom in 63% of patients with lymphomatous pleural effusions, as noted by the American College of Chest Physicians 1
The effusion characteristics include serous, hemorrhagic, or chylous effusions, with chylous effusions occurring in approximately 5% of cases, as reported by the American Thoracic Society 1

The presence of ascites or pleural effusion is a specific indication to initiate systemic therapy in follicular lymphoma, even in otherwise asymptomatic patients, as recommended by the European Society for Medical Oncology and the National Comprehensive Cancer Network 2, 3, 4
Other indications for treatment include B symptoms, hematopoietic impairment, bulky disease, vital organ compression, and rapid lymphoma progression, as recommended by the European Society for Medical Oncology and the National Comprehensive Cancer Network 2, 4

The cytologic yield is relatively poor in lymphoma compared to other malignancies, ranging from 31-55%, with the lowest yield in Hodgkin's disease, as reported by the American College of Chest Physicians 1
Superior diagnostic methods include thoracoscopy with chromosome analysis, which has a sensitivity of approximately 85%, and flow cytometry to demonstrate clonality, which has a sensitivity and specificity of 100% when combined with morphology, as recommended by the American Thoracic Society 1, 5

Systemic chemotherapy is the treatment of choice, not local pleural procedures, as recommended by the American College of Chest Physicians and the European Respiratory Society 1, 6
Approximately half of patients achieve complete effusion resolution during systemic therapy, and response should be assessed during the first few cycles of chemotherapy, as noted by the European Respiratory Society 7, 6
Prognostic significance is poor, with average survival after first thoracentesis being only 6-7 months, as reported by the American College of Chest Physicians 1

The European Respiratory Society and American College of Chest Physicians guidelines explicitly state that systemic therapy is the treatment of choice for lymphoma-associated pleural effusions, with octreotide considered for chylous effusions 8, 9

Systemic chemotherapy should be initiated as first-line treatment for non-chylous pleural effusions, with effusions drained prior to commencing chemotherapy to avoid potential accumulation of chemotherapy in undrained effusions 8, 9, 10

Octreotide should not be used for non-chylous lymphoma effusions, as there is no evidence supporting its use for typical serous or hemorrhagic lymphoma effusions 8, 9